BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 35856357)

  • 1. Treatments for relapsed-refractory diffuse large B-cell lymphoma: comparison of overall survival outcomes observed with four novel agents.
    Messori A; Caccese E
    Eur Rev Med Pharmacol Sci; 2022 Jul; 26(13):4666-4670. PubMed ID: 35856357
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatments for Relapsed-Refractory Diffuse Large B-cell Lymphoma: A Preliminary Evaluation of the Place in Therapy of Glofitamab, a Bispecific Monoclonal Antibody.
    Messori A; Rivano M; Mengato D; Chiumente M
    Cureus; 2022 Dec; 14(12):e33169. PubMed ID: 36726938
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tafasitamab Plus Lenalidomide Versus 3 Rituximab-Based Treatments for Non-Transplant Eligible Relapsed/Refractory Diffuse Large B-Cell Lymphoma: A Matching-Adjusted Indirect Comparison.
    Cordoba R; Prawitz T; Westley T; Sharma A; Ambarkhane S; Kapetanakis V; Sabatelli L
    Adv Ther; 2022 Jun; 39(6):2668-2687. PubMed ID: 35403948
    [TBL] [Abstract][Full Text] [Related]  

  • 4. RE-MIND2: comparative effectiveness of tafasitamab plus lenalidomide versus polatuzumab vedotin/bendamustine/rituximab (pola-BR), CAR-T therapies, and lenalidomide/rituximab (R2) based on real-world data in patients with relapsed/refractory diffuse large B-cell lymphoma.
    Nowakowski GS; Yoon DH; Mondello P; Joffe E; Peters A; Fleury I; Greil R; Ku M; Marks R; Kim K; Zinzani PL; Trotman J; Sabatelli L; Waltl EE; Winderlich M; Sporchia A; Kurukulasuriya NC; Cordoba R; Hess G; Salles G
    Ann Hematol; 2023 Jul; 102(7):1773-1787. PubMed ID: 37171597
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tafasitamab plus lenalidomide in relapsed or refractory diffuse large B-cell lymphoma (L-MIND): a multicentre, prospective, single-arm, phase 2 study.
    Salles G; Duell J; González Barca E; Tournilhac O; Jurczak W; Liberati AM; Nagy Z; Obr A; Gaidano G; André M; Kalakonda N; Dreyling M; Weirather J; Dirnberger-Hertweck M; Ambarkhane S; Fingerle-Rowson G; Maddocks K
    Lancet Oncol; 2020 Jul; 21(7):978-988. PubMed ID: 32511983
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tafasitamab and lenalidomide for relapsed/refractory diffuse large B-cell lymphoma in a patient on chronic intermittent hemodialysis.
    Moore DC; Eagers KA; Janes A; Pineda-Roman M
    J Oncol Pharm Pract; 2023 Jan; 29(1):239-241. PubMed ID: 35585701
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical Treatment Guidelines for Tafasitamab Plus Lenalidomide in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma.
    Nedved A; Maddocks K; Nowakowski GS
    Oncologist; 2023 Mar; 28(3):199-207. PubMed ID: 36648324
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Economic evaluation of polatuzumab-bendamustine-rituximab
    Calamia M; McBride A; Abraham I
    J Med Econ; 2021 Nov; 24(sup1):14-24. PubMed ID: 34866523
    [TBL] [Abstract][Full Text] [Related]  

  • 9. RE-MIND: Comparing Tafasitamab + Lenalidomide (L-MIND) with a Real-world Lenalidomide Monotherapy Cohort in Relapsed or Refractory Diffuse Large B-cell Lymphoma.
    Zinzani PL; Rodgers T; Marino D; Frezzato M; Barbui AM; Castellino C; Meli E; Fowler NH; Salles G; Feinberg B; Kurukulasuriya NC; Tillmanns S; Parche S; Dey D; Fingerle-Rowson G; Ambarkhane S; Winderlich M; Nowakowski GS
    Clin Cancer Res; 2021 Nov; 27(22):6124-6134. PubMed ID: 34433649
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Newly approved anti-CD19 monoclonal antibodies for the treatment of relapsed or refractory diffuse large B-cell lymphoma.
    Davis JA; Shockley A; Glode AE
    J Oncol Pharm Pract; 2022 Apr; 28(3):686-690. PubMed ID: 35037773
    [No Abstract]   [Full Text] [Related]  

  • 11. Long-term outcomes from the Phase II L-MIND study of tafasitamab (MOR208) plus lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma.
    Duell J; Maddocks KJ; González-Barca E; Jurczak W; Liberati AM; De Vos S; Nagy Z; Obr A; Gaidano G; Abrisqueta P; Kalakonda N; André M; Dreyling M; Menne T; Tournilhac O; Augustin M; Rosenwald A; Dirnberger-Hertweck M; Weirather J; Ambarkhane S; Salles G
    Haematologica; 2021 Sep; 106(9):2417-2426. PubMed ID: 34196165
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel agents in relapsed/refractory diffuse large B-cell lymphoma.
    Varma G; Goldstein J; Advani RH
    Hematol Oncol; 2023 Jun; 41 Suppl 1():92-106. PubMed ID: 37294966
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anti-CD19 monoclonal antibodies for the treatment of relapsed or refractory B-cell malignancies: a narrative review with focus on diffuse large B-cell lymphoma.
    Zinzani PL; Minotti G
    J Cancer Res Clin Oncol; 2022 Jan; 148(1):177-190. PubMed ID: 34741682
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Improved Efficacy of Tafasitamab plus Lenalidomide versus Systemic Therapies for Relapsed/Refractory DLBCL: RE-MIND2, an Observational Retrospective Matched Cohort Study.
    Nowakowski GS; Yoon DH; Peters A; Mondello P; Joffe E; Fleury I; Greil R; Ku M; Marks R; Kim K; Zinzani PL; Trotman J; Huang D; Waltl EE; Winderlich M; Kurukulasuriya NC; Ambarkhane S; Hess G; Salles G
    Clin Cancer Res; 2022 Sep; 28(18):4003-4017. PubMed ID: 35674661
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Polatuzumab vedotin plus obinutuzumab and lenalidomide in patients with relapsed or refractory follicular lymphoma: a cohort of a multicentre, single-arm, phase 1b/2 study.
    Diefenbach C; Kahl BS; McMillan A; Briones J; Banerjee L; Cordoba R; Miall F; Burke JM; Hirata J; Jiang Y; Paulson JN; Chang YM; Musick L; Abrisqueta P
    Lancet Haematol; 2021 Dec; 8(12):e891-e901. PubMed ID: 34826412
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Challenges and Opportunities in the Management of Diffuse Large B-Cell Lymphoma in Older Patients.
    Di M; Huntington SF; Olszewski AJ
    Oncologist; 2021 Feb; 26(2):120-132. PubMed ID: 33230948
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tafasitamab for patients with relapsed or refractory diffuse large B-cell lymphoma: final 5-year efficacy and safety findings in the phase II L-MIND study.
    Duell J; Abrisqueta P; Andre M; Gaidano G; Gonzales-Barca E; Jurczak W; Kalakonda N; Liberati AM; Maddocks KJ; Menne T; Nagy Z; Tournilhac O; Kuffer C; Bakuli A; Amin A; Gurbanov K; Salles G
    Haematologica; 2024 Feb; 109(2):553-566. PubMed ID: 37646664
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Loncastuximab tesirine for treatment of relapsed or refractory diffuse large B cell lymphoma.
    Goparaju K; Caimi PF
    Expert Opin Biol Ther; 2021 Nov; 21(11):1373-1381. PubMed ID: 34505550
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New and emerging therapies for the treatment of relapsed/refractory diffuse large B-cell lymphoma.
    Moore DC; Peery MR; Tobon KA; Raheem F; Hwang GS; Alhennawi L; Hughes ME
    J Oncol Pharm Pract; 2022 Dec; 28(8):1848-1858. PubMed ID: 35469489
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tafasitamab and lenalidomide in large B-cell lymphoma: real-world outcomes in a multicenter retrospective study.
    Qualls DA; Lambert N; Caimi PF; Merrill M; Pullarkat P; Godby RC; Bond DA; Wehmeyer GT; Romancik J; Amoozgar B; Leslie L; Nastoupil LJ; Crombie JL; Abramson JS; Khurana A; Nowakowski GS; Maddocks K; Rutherford SC; Kahl B; Okwali M; Buege MJ; Seshan V; Batlevi CL; Salles G
    Blood; 2023 Dec; 142(26):2327-2331. PubMed ID: 37738563
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.